Cargando…

Identifying the Presence of Prostate Cancer in Individuals with PSA Levels <20 ng ml(−1) Using Computational Data Extraction Analysis of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data

Determining whether an asymptomatic individual with Prostate-Specific Antigen (PSA) levels below 20 ng ml(−1) has prostate cancer in the absence of definitive, biopsy-based evidence continues to present a significant challenge to clinicians who must decide whether such individuals with low PSA value...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cosma, Georgina, McArdle, Stéphanie E., Reeder, Stephen, Foulds, Gemma A., Hood, Simon, Khan, Masood, Pockley, A. Graham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741695/ https://www.ncbi.nlm.nih.gov/pubmed/29326690 http://dx.doi.org/10.3389/fimmu.2017.01771

Ejemplares similares

Prostate Cancer: Early Detection and Assessing Clinical Risk Using Deep Machine Learning of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data
por: Cosma, Georgina, et al.
Publicado: (2021)

Identifying prostate cancer and its clinical risk in asymptomatic men using machine learning of high dimensional peripheral blood flow cytometric natural killer cell subset phenotyping data
por: Hood, Simon P, et al.
Publicado: (2020)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
por: Lee, Seung Hwan, et al.
Publicado: (2011)

Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation
por: Hood, Simon P., et al.
Publicado: (2019)

Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL
por: Hinev, Alexander I., et al.
Publicado: (2012)

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
por: Shaida, Nadeem, et al.
Publicado: (2009)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml(-1) and 10.1–20.0 ng ml(-1): a multicenter study
por: Lin, Yu-Rong, et al.
Publicado: (2015)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
por: Kumar, Niraj, et al.
Publicado: (2019)

Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy
por: Wu, Qiang, et al.
Publicado: (2021)

The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS
por: Adegun, Patrick Temi, et al.
Publicado: (2015)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
por: Vukovic, I., et al.
Publicado: (2017)

The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL
por: Wang, Zhi-bing, et al.
Publicado: (2021)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report
por: Johnson, Michael H., et al.
Publicado: (2015)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection
por: Zheng, Yuxiao, et al.
Publicado: (2016)

AB013. The study on the diagnostic value of f/tPSA to the prostate cancer with tPSA greater than 10 ng/mL
por: Li, Yan-Feng, et al.
Publicado: (2016)

Correlation of Serum Androgens and Pituitary Hormone Levels with Serum PSA Less Than 2.5 NG/ML
por: Sofikerim, Mustafa, et al.
Publicado: (2007)

A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml
por: Chavan, Sushant V., et al.
Publicado: (2011)

Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database
por: Lonergan, Peter E., et al.
Publicado: (2021)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
por: Busato, W. F. S., et al.
Publicado: (2015)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml(–1)
por: Wang, Cheng, et al.
Publicado: (2021)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

Impact of Comorbidity, Race, and Marital Status in Men Referred for Prostate Biopsy with PSA >20 ng/mL: A Pilot Study in High-Risk Patients
por: Klaassen, Zachary, et al.
Publicado: (2014)

Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4–20 ng/mL
por: Zheng, Yuxin, et al.
Publicado: (2022)

Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0–25.0 ng ml(-1) in Western China
por: Gao, Xue-Dan, et al.
Publicado: (2021)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA
por: Zhao, Jing, et al.
Publicado: (2016)

Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
por: Su, Rui, et al.
Publicado: (2022)

DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is ≥10 ng/ml
por: Sun, Hongmei, et al.
Publicado: (2022)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
por: Chen, Rui, et al.
Publicado: (2015)

Comparison of (68)Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20 ng/ml before the initial biopsy
por: Li, Yu, et al.
Publicado: (2020)

Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China
por: Dai, Zhihong, et al.
Publicado: (2021)

Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL
por: Zhou, Yongqiang, et al.
Publicado: (2017)

Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL
por: Lu, Yangbai, et al.
Publicado: (2022)

Clinical Significance of Free-to-Total Prostate-Specific Antigen (PSA) Ratio in Advanced Prostate Cancer Patients with PSA Less than 0.1 ng/ml after Hormone Treatment
por: Kim, Dae Il, et al.
Publicado: (2012)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng ml(−1)
por: Tan, Lincoln GL, et al.
Publicado: (2017)

The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria
por: Ezenwa, E.V., et al.
Publicado: (2012)

Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with PSA levels between 2.6 and 10.0 ng/mL
por: Castro, Hugo A. Socrates, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_409ic774i88l2qg197ebuv7p46